Skip to main content

Scholarship for the best clinical research idea

Coins and plants

Do you have an idea for a multicenter clinical study? If you work in a company that is part of the National Clinical Network, outside of OUS or Diakonhjemmet Hospital, you can apply. If your idea is good enough, you can get seed funding to develop it! The application deadline is January 20, 2026.

REMEDY collaborates with the Norwegian Rheumatological Society (NRF) to stimulate the development of good research projects from all over Norway within rheumatology and the musculoskeletal field. A seed grant is now being announced for the year's best project idea from REMEDY's national network.

 REMEDY's National Clinical Network, in collaboration with the Norwegian Rheumatological Association, announces a grant for the best clinical research idea

The goal of the REMEDY/NRF network grant

To help develop a research idea into a competitive application for external funding.

The application must address a research idea that could contribute to improving treatment for people with rheumatic disease or musculoskeletal disease. The idea must involve collaboration between multiple institutions (multicenter studies).

The initiator or institution that comes up with the idea will lead the development of the project and the application. The project group must include at least one member of the Norwegian Rheumatological Society. The applicant/project leader cannot be employed at OUS (partner in REMEDY) or Diakonhjemmet Hospital (host institution for REMEDY).

Scholarships and research support                            

  • Seed funds of NOK 100,000 that can be used to buy out time to develop a project outline, protocol and application(s) for research funding. NOK 50,000 is funded by NRF and reserved for buyout by a member of NRF.
  • Participation in REMEDY's research seminar at Sundvolden Hotell on 11-12 March 2026, including travel/accommodation. Here, the winner will present their project idea in a group session, and receive feedback and guidance from experienced researchers.
  • In addition, the winner will have the opportunity to discuss the development of the project in a meeting with relevant REMEDY work packages and REMEDY's Clinical Trial Unit (e.g. statistician/biobank advisor/CTIS advisor).

Assessment committee 

The evaluation of the applications is done by a committee with two members from the board of the Norwegian Rheumatological Society, leaders of the National Network in REMEDY and work package leaders in REMEDY's work package 1, as well as a representative from the REMEDY patient council and a representative from the Norwegian Rheumatology Association. The evaluation committee will select a winner based on the following evaluation criteria, where the project has:

  • Potential to become a multicenter clinical study preferably within the definition of the Ministry of Health and Care Services (HOD)'s definition of clinical treatment studies (KBS): A clinical treatment study is defined as all clinical treatment and rehabilitation studies that can affect the patient course of the research participants.
  • Potential to provide better patient care in rheumatic and musculoskeletal diseases
  • Potential to change clinical practice
  • Innovative and feasible
  • Originality and relevance to patients and/or healthcare within rheumatology
  • Realistic plan for developing project outline and plan for applications for funding

📍Who can apply: Applicant must be employed at a participating unit in the National Clinical Network. Applicant/project manager cannot be employed at OUS (partner in REMEDY) or Diakonhjemmet Hospital (host institution for REMEDY).

📍 Application deadline: January 20, 2026

📍 Application must be submitted via online form: https://nettskjema.no/a/bestekliniskeforskningside2026

 📍Attachments to application:

1️⃣CV for applicant (max 2 pages) with publication list (max 3 pages)

2️⃣Project description (with the following layout, can include up to 4 tables/figures that do not count in the word count):

  • Background, rationale and research questions (max 400 words)
  • Expected benefit (max 200 words)
  • Patient group(s) – inclusion and exclusion criteria (max 200 words)
  • Methods/intervention(s), outcome measures and duration of follow-up (max 400 words)
  • User participation (describe the involvement of users in the various phases of the project) (max. 200 words)
  • Plan for further development and application for funding? What help do you need in this phase? (max 400 words)

The freshest

More news from REMEDY